ANIK Earnings Date: Nov 6, 2026 (Estimated) — Anika Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is ANIK's next earnings date?
Anika Therapeutics, Inc. (ANIK) is expected to report Q3 2026 earnings on Friday, November 6, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.42 on revenue of $29.4M.
How did ANIK do in its last earnings report?
In its most recent report on Jul 29, 2026 (Q2 2026), Anika Therapeutics, Inc. posted EPS of $0.42 versus the -$0.01 estimate, a beat of 4300.0%. Revenue was $32.6M against a $29.2M estimate. The stock's 1-day post-earnings move was +6.7%.
How much does ANIK stock move after earnings?
ANIK beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 15.7% (up or down) in the day after earnings.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-29 | Q2 2026 | -0.01 | 0.42 | +4300.00% | $32.6M | ✅ Beat | +6.73% | +29.44% | +43.10% |
| 2026-04-29 | Q1 2026 | -0.04 | 0.27 | +775.00% | $29.6M | ✅ Beat | -18.81% | -2.03% | -2.36% |
| 2026-02-26 | Q4 2025 | -0.06 | 0.31 | +616.67% | $30.6M | ✅ Beat | +16.91% | +31.26% | +34.83% |
| 2025-11-05 | Q3 2025 | -0.06 | 0.04 | +166.67% | $27.8M | ✅ Beat | +2.28% | +5.19% | -1.45% |
| 2025-07-30 | Q2 2025 | -0.21 | -0.13 | +38.10% | $28.2M | ✅ Beat | -27.42% | -25.18% | -17.74% |
| 2025-03-12 | Q4 2024 | 0.09 | -0.03 | -133.33% | $30.6M | ❌ Miss | -11.10% | -6.78% | -20.51% |
| 2024-10-31 | Q3 2024 | -0.01 | -0.25 | -2400.00% | $38.8M | ❌ Miss | -30.67% | -30.02% | -28.20% |
| 2024-05-08 | Q1 2024 | -0.19 | 0.09 | +147.37% | $40.5M | ✅ Beat | -11.28% | -8.39% | -9.41% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY24 · $14.3M total
| Segment | Share | Revenue | YoY | Q1 FY23 | Q2 FY23 | Q3 FY23 | Q4 FY23 |
|---|---|---|---|---|---|---|---|
| Joint Preservation and Restoration | 83.4% | $11.9M | -11.3% | $13.5M | $12.7M | $13.5M | $15.3M |
| Non-Orthopedic | 16.6% | $2.4M | -23.6% | $1.8M | $2.3M | $3.1M | $2.6M |
By region
Q2 FY26 · $26.6M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 74.3% | $19.8M | +10.5% | $25.5M | $16.4M | $17.9M | $17.4M |
| Europe | 25.7% | $6.8M | +43.9% | $7.7M | $5.8M | $4.8M | $5.7M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.